FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. <i>See</i> Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APF	ROVAL
OMB Number:	3235-0287
Estimated average	burden

hours p	er response:	0.5
Estimat	ted average burden	

1. Name and Address of Reporting Person* <u>ZERBE ROBERT L MD</u>			2. Issuer Name and Ticker or Trading Symbol <u>AP PHARMA INC /DE/</u> [APPA]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)				
					Director	10% Owner		
-					Officer (give title	Other (specify		
(Last)	(First)	(Middle)	3. Date of Earliest Transaction (Month/Day/Year)		below)	below)		
	INC.		05/20/2010	1				
A.P. PHARMA,	INC.							
123 SAGINAW	DRIVE							
	211.12		4. If Amendment, Date of Original Filed (Month/Day/Year)	6 India	/idual or Joint/Group Fili	na (Chook Applicable		
				Line)	nuuai or Joint/Group Fill	ny (Check Applicable		
(Street)					Form filed by One De	norting Deres		
REDWOOD	~	0.40.00			Form filed by One Re	porting Person		
CITY	CA	94063			Form filed by More the Person	an One Reporting		
			-					
(City)	(State)	(Zip)						

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transa Code (8)		Disposed Of (D) (Instr. 3, 4 and 5)		Securities Beneficially	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
			Code	v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		(11311.4)
Common Stock	05/20/2010		A		95,891 ⁽¹⁾	Α	\$ <mark>0</mark>	202,072	D	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Transaction Code (Instr. 8)		Transaction Code (Instr. 8)		of		action (Instr. Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4		of Expiration Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4		Expiration Date (Month/Day/Year)		Expiration Date		Expiration Date		Expiration Date		Expiration Date		Ind 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares																		

Explanation of Responses:

1. Vesting will occur in equal increments, 1/2 to vest in 6 months from the date of grant and the balance to vest on the day prior to the Company's next Annual Meeting.

By: Natalie Godfrey, Attorney-05/26/2010 in-fact For: Robert L. Zerbe Date

** Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.